Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

  • Mateo, F
  • Arenas, E J
  • Aguilar, H
  • Serra-Musach, J
  • de Garibay, G Ruiz
  • Boni, J
  • Maicas, M
  • Du, S
  • Iorio, F
  • Herranz-Ors, C
  • Islam, A
  • Prado, X
  • Llorente, A
  • Petit, A
  • Vidal, A
  • Català, I
  • Soler, T
  • Venturas, G
  • Rojo-Sebastian, A
  • Serra, H
  • Cuadras, D
  • Blanco, I
  • Lozano, J
  • Canals, F
  • Sieuwerts, A M
  • de Weerd, V
  • Look, M P
  • Puertas, S
  • García, N
  • Perkins, A S
  • Bonifaci, N
  • Skowron, M
  • Gómez-Baldó, L
  • Hernández, V
  • Martínez-Aranda, A
  • Martínez-Iniesta, M
  • Serrat, X
  • Cerón, J
  • Brunet, J
  • Barretina, M P
  • Gil, M
  • Falo, C
  • Fernández, A
  • Morilla, I
  • Pernas, S
  • Plà, M J
  • Andreu, X
  • Seguí, M A
  • Ballester, R
  • Castellà, E
  • Nellist, M
  • Morales, S
  • Valls, J
  • Velasco, A
  • Matias-Guiu, X
  • Figueras, A
  • Sánchez-Mut, J V
  • Sánchez-Céspedes, M
  • Cordero, A
  • Gómez-Miragaya, J
  • Palomero, L
  • Gómez, A
  • Gajewski, T F
  • Cohen, E E W
  • Jesiotr, M
  • Bodnar, L
  • Quintela-Fandino, M
  • López-Bigas, N
  • Valdés-Mas, R
  • Puente, X S
  • Viñals, F
  • Casanovas, O
  • Graupera, M
  • Hernández-Losa, J
  • Ramón Y Cajal, S
  • García-Alonso, L
  • Saez-Rodriguez, J
  • Esteller, M
  • Sierra, A
  • Martín-Martín, N
  • Matheu, A
  • Carracedo, A
  • González-Suárez, E
  • Nanjundan, M
  • Cortés, J
  • Lázaro, C
  • Odero, M D
  • Martens, J W M
  • Moreno-Bueno, G
  • Barcellos-Hoff, M H
  • Villanueva, A
  • Gomis, R R
  • Pujana, M A
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Repisalud
Publication Artículo científico (JournalArticle)

Study of breast cancer incidence in patients of lymphangioleiomyomatosis.

  • Nuñez, Olivier
  • Román, Antonio
  • Johnson, Simon R
  • Inoue, Yoshikazu
  • Hirose, Masaki
  • Casanova, Álvaro
  • de Garibay, Gorka Ruiz
  • Herranz, Carmen
  • Bueno-Moreno, Gema
  • Boni, Jacopo
  • Mateo, Francesca
  • Petit, Anna
  • Climent, Fina
  • Soler, Teresa
  • Vidal, August
  • Sánchez-Mut, José Vicente
  • Esteller, Manel
  • López, José Ignacio
  • García, Nadia
  • Gumà, Anna
  • Ortega, Raúl
  • Plà, María Jesús
  • Campos, Miriam
  • Ansótegui, Emilio
  • Molina-Molina, María
  • Valenzuela, Claudia
  • Ussetti, Piedad
  • Laporta, Rosalía
  • Ancochea, Julio
  • Xaubet, Antoni
  • Pujana, Miguel Angel
  • Pollan-Santamaria, Marina
Molecular evidence has linked the pathophysiology of lymphangioleiomyomatosis (LAM) to that of metastatic breast cancer. Following on this observation, we assessed the association between LAM and subsequent breast cancer. An epidemiological study was carried out using three LAM country cohorts, from Japan, Spain, and the United Kingdom. The number of incident breast cancer cases observed in these cohorts was compared with the number expected on the basis of the country-specific incidence rates for the period 2000-2014. Immunohistochemical studies and exome sequence analysis were performed in two and one tumors, respectively. All cohorts revealed breast cancer standardized incidence ratios (SIRs) ≥ 2.25. The combined analysis of all cases or restricted to pre-menopausal age groups revealed significantly higher incidence of breast cancer: SIR = 2.81, 95 % confidence interval (CI) = 1.32-5.57, P = 0.009; and SIR = 4.88, 95 % CI = 2.29-9.99, P = 0.0007, respectively. Immunohistochemical analyses showed positivity for known markers of lung metastatic potential. This study suggests the existence of increased breast cancer risk among LAM patients. Prospective studies may be warranted to corroborate this result, which may be particularly relevant for pre-menopausal women with LAM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, F.
  • Arenas, E. J.
  • Aguilar, H.
  • Serra-Musach, J.
  • Ruiz de Garibay, G.
  • Boni, J.
  • Maicas, M.
  • Du, S.
  • Lorio, F.
  • Herranz-Ors, C.
  • Islam, A.
  • Prado, X.
  • Llorente, A.
  • Petit, A.
  • Vidal, A.
  • Catalá, I.
  • Soler, T.
  • Venturas, G.
  • Rojo-Sebastian, A.
  • Serra, H.
  • Cuadras, D.
  • Blanco, I.
  • Lozano, J.
  • Canals, F.
  • Sieuwerts, A. M.
  • Weerd, V. de
  • Look, M. P.
  • Puertas, S.
  • García, N.
  • Perkins, A. S.
  • Bonifaci, N.
  • Skowron, M.
  • Gómez-Baldó, L.
  • Hernández, V.
  • Martínez-Aranda, A.
  • Martínez-Iniesta, M.
  • Serrat, X.
  • Cerón, Julián
  • Brunet, J.
  • Barretina, M. P.
  • Gil, M.
  • Falo, C.
  • Fernández, A.
  • Morilla, I.
  • Pernas, S.
  • Plà, M. J.
  • Andreu, X.
  • Seguí, M. A.
  • Ballester, R.
  • Castellà, E.
  • Nellist. M.
  • Morales, S.
  • Valls, J.
  • Velasco, A.
  • Matias-Guiu, X.
  • Figueras, A.
  • Sánchez-Mut, José Vicente
  • Sánchez-Céspedes, M.
  • Cordero, A.
  • Gómez-Miragaya, J.
  • Palomero, L.
  • Gómez, A.
  • Gajewski, T. F.
  • Cohen, E. E. W.
  • Jesiotr, M.
  • Bodnar, L.
  • Quintela-Fandino, M.
  • López-Bigas, N.
  • Valdés-Mas, R.
  • Puente, X. S.
  • Viñals, F.
  • Casanovas, O.
  • Graupera, M.
  • Hernández-Losa, L.
  • Ramón y Cajal, S.
  • García-Alonso, L.
  • Sáez-Rodríguez, J.
  • Esteller, M.
  • Sierra, A.
  • Martín-Martín, N.
  • Matheu, A.
  • Carracedo, A.
  • González-Suárez, E.
  • Nanjundan, M.
  • Cortés, J.
  • Lázaro, C.
  • Odero, M. D.
  • Martens, J. W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, M. H.
  • Villanueva, A.
  • Gomis, R. R.
  • Pujana, M. A.
13 páginas, 7 figuras, Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure., This study was supported by the following bodies and grants: the Scientific Foundation ‘Asociación Española Contra el Cáncer’ (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodríguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’, MINECO grants SAF2010- 20203 and SAF2013-46196; and the Telemaraton 2014 ‘Todos Somos Raros, Todos Somos Únicos’ grant P35. EJA was supported by ‘la Caixa’ PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine

  • Castellsagué, Joan|||0000-0002-2579-3137
  • Gel, Bernat|||0000-0001-8878-349X
  • Fernández-Rodríguez, Juana
  • Llatjós, Roger
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Pérez-Sidelnikova, Diana
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Viñals, Joan Maria
  • Vidal, August|||0000-0001-5727-2099
  • Valdés-Mas, Rafael
  • Terribas, Ernest
  • López-Doriga, Adriana
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Capella, Gabriel|||0000-0002-4669-7320
  • Puente, Xose S.|||0000-0001-9525-1483
  • Serra, Eduard|||0000-0003-2895-9857
  • Villanueva Garatachea, Alberto
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that can arise either sporadically or in association with neurofibromatosis type 1 (NF1). These aggressive malignancies confer poor survival, with no effective therapy available. We present the generation and characterization of five distinct MPNST orthoxenograft models for preclinical testing and personalized medicine. Four of the models are patient-derived tumor xenografts (PDTX), two independent MPNSTs from the same NF1 patient and two from different sporadic patients. The fifth model is an orthoxenograft derived from an NF1-related MPNST cell line. All MPNST orthoxenografts were generated by tumor implantation, or cell line injection, next to the sciatic nerve of nude mice, and were perpetuated by 7-10 mouse-to-mouse passages. The models reliably recapitulate the histopathological properties of their parental primary tumors. They also mimic distal dissemination properties in mice. Human stroma was rapidly lost after MPNST engraftment and replaced by murine stroma, which facilitated genomic tumor characterization. Compatible with an origin in a catastrophic event and subsequent genome stabilization, MPNST contained highly altered genomes that remained remarkably stable in orthoxenograft establishment and along passages. Mutational frequency and type of somatic point mutations were highly variable among the different MPNSTs modeled, but very consistent when comparing primary tumors with matched orthoxenografts generated. Unsupervised cluster analysis and principal component analysis (PCA) using an MPNST expression signature of ~1,000 genes grouped together all primary tumor-orthoxenograft pairs. Our work points to differences in the engraftment process of primary tumors compared with the engraftment of established cell lines. Following standardization and extensive characterization and validation, the orthoxenograft models were used for initial preclinical drug testing. Sorafenib (a BRAF inhibitor), in combination with doxorubicin or rapamycin, was found to be the most effective treatment for reducing MPNST growth. The development of genomically well-characterized preclinical models for MPNST allowed the evaluation of novel therapeutic strategies for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cancer network activity associated with therapeutic response and synergism

  • Serra-Musach, Jordi
  • Mateo, Francesca|||0000-0002-2342-7010
  • Capdevila Busquets, Eva
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Zhang, Xiaohu
  • Guha, Raj
  • Thomas, Craig J.
  • Grueso, Judit|||0000-0003-1093-7940
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Jaeger, Samira
  • Heyn, Holger|||0000-0002-3276-1889
  • Vizoso, Miguel
  • Pérez Montero, Hector|||0000-0002-9756-5088
  • Cordero, Alex
  • González Suarez, Eva
  • Esteller, M.|||0000-0003-4490-6093
  • Moreno-Bueno, Gema
  • Tjärnberg, Andreas
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Serra, Violeta|||0000-0001-6620-1065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Benson, Mikael
  • Gustafsson, Mika
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Aloy, Patrick|||0000-0002-3557-0236
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. We reasoned that network analysis of omic data could help to achieve this goal. A measure of "cancer network activity" (CNA) was implemented based on a previously defined network feature of communicability. The network nodes and edges corresponded to human proteins and experimentally identified interactions, respectively. The edges were weighted proportionally to the expression of the genes encoding for the corresponding proteins and relative to the number of direct interactors. The gene expression data corresponded to the basal conditions of 595 human cancer cell lines. Therapeutic responses corresponded to the impairment of cell viability measured by the half maximal inhibitory concentration (IC) of 130 drugs approved or under clinical development. Gene ontology, signaling pathway, and transcription factor-binding annotations were taken from public repositories. Predicted synergies were assessed by determining the viability of four breast cancer cell lines and by applying two different analytical methods. The effects of drug classes were associated with CNAs formed by different cell lines. CNAs also differentiate target families and effector pathways. Proteins that occupy a central position in the network largely contribute to CNA. Known key cancer-associated biological processes, signaling pathways, and master regulators also contribute to CNA. Moreover, the major cancer drivers frequently mediate CNA and therapeutic differences. Cell-based assays centered on these differences and using uncorrelated drug effects reveals novel synergistic combinations for the treatment of breast cancer dependent on PI3K-mTOR signaling. Cancer therapeutic responses can be predicted on the basis of a systems-level analysis of molecular interactions and gene expression. Fundamental cancer processes, pathways, and drivers contribute to this feature, which can also be exploited to predict precise synergistic drug combinations. The online version of this article (doi:10.1186/s13073-016-0340-x) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Kuchenbaecker, Karoline|||0000-0001-9726-603X
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Wang, Xianshu
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Librado, Pablo
  • Sánchez-Gracia, Alejandro|||0000-0003-4543-4577
  • Rozas, Julio|||0000-0002-6839-9148
  • Bonifaci, Núria|||0000-0002-8193-6825
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Pankratz, Vernon S.
  • Islam, Abul
  • Mateo, Francesca|||0000-0002-2342-7010
  • Berenguer-Llergo, Antoni|||0000-0002-3742-8161
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Català, Isabel
  • Brunet, Joan|||0000-0003-1945-3512
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Tornero, Eva
  • Benitez, Javier|||0000-0002-0923-7202
  • Osorio, Ana|||0000-0001-8124-3984
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Aittomäki, Kristiina
  • Arun, Banu K.
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Walsh, Christine
  • Lester, Jenny
  • Greene, Mark H.|||0000-0003-1852-9239
  • Mai, Phuong L.
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Rebbeck, Timothy R.
  • Barkardottir, Rosa B.
  • Jakubowska, Anna|||0000-0002-5650-0501
  • Lubinski, Jan|||0000-0003-2931-3003
  • Durda, Katarzyna
  • Jaworska-Bieniek, Katarzyna
  • Claes, Kathleen|||0000-0003-0841-7372
  • Van Maerken, Tom
  • Diez, Orland|||0000-0001-7339-0570
  • Hansen, Thomas V.
  • Jønson, Lars
  • Gerdes, Anne-Marie
  • Ejlertsen, Bent
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • Caldes, Trinidad
  • Dunning, Alison M.
  • Oliver, Clare
  • Fineberg, Elena
  • Cook, Margaret
  • Peock, Susan
  • McCann, Emma
  • Murray, Alex
  • Jacobs, Chris
  • Pichert, Gabriella
  • Lalloo, Fiona
  • Chu, Carol
  • Dorkins, Huw
  • Paterson, Joan
  • Ong, Kai-Ren
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Hogervorst, Frans B. L.
  • van der Hout, Annemarie H.
  • Seynaeve, Caroline
  • van der Luijt, Rob B.
  • Ligtenberg, Marjolijn J. L.
  • Devilee, Peter|||0000-0002-8023-2009
  • Wijnen, Juul T.
  • Rookus, Matti A.
  • Meijers-Heijboer, Hanne E. J.
  • Blok, Marinus J.|||0000-0002-7935-5933
  • van den Ouweland, Ans M. W.
  • Aalfs, Cora M.
  • Rodriguez, Gustavo C.
  • Phillips, Kelly-Anne|||0000-0002-0475-1771
  • Piedmonte, Marion
  • Nerenstone, Stacy R.
  • Bae-Jump, Victoria L.
  • O'Malley, David M.
  • Ratner, Elena S.
  • Schmutzler, Rita K.
  • Wappenschmidt, Barbara
  • Rhiem, Kerstin
  • Engel, Christoph
  • Meindl, Alfons
  • Ditsch, Nina
  • Arnold, Norbert
  • Plendl, Hansjoerg J.
  • Niederacher, Dieter
  • Sutter, Christian|||0000-0003-4051-5888
  • Wang-Gohrke, Shan
  • Steinemann, Doris|||0000-0001-8797-0816
  • Preisler-Adams, Sabine
  • Kast, Karin|||0000-0001-6531-755X
  • Varon-Mateeva, Raymonda
  • Gehrig, Andrea
  • Bojesen, Anders|||0000-0003-4289-8595
  • Pedersen, Inge Sokilde
  • Sunde, Lone
  • Jensen, Uffe Birk
  • Thomassen, Mads
  • Kruse, Torben A.
  • Foretova, Lenka|||0000-0003-0494-2620
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Bernard, Loris
  • Peissel, Bernard|||0000-0001-9233-3571
  • Scuvera, Giulietta
  • Manoukian, Siranoush
  • Radice, Paolo|||0000-0001-6298-4111
  • Ottini, Laura
  • Montagna, Marco
  • Agata, Simona
  • Maugard, Christine
  • Simard, Jacques|||0000-0001-6906-3390
  • Soucy, Penny
  • Berger, Andreas|||0000-0001-5865-6609
  • Fink-Retter, Anneliese
  • Singer, Christian F.
  • Rappaport, Christine
  • Geschwantler-Kaulich, Daphne
  • Tea, Muy-Kheng
  • Pfeiler, Georg
  • John, Esther M.
  • Miron, Alex
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Terry, Mary Beth
  • Chung, Wendy
  • Daly, Mary B.
  • Goldgar, David E.
  • Janavicius, Ramunas
  • Dorfling, Cecilia M.
  • van Rensburg, Elisabeth J.
  • Fostira, Florentia
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Garber, Judy
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Olah, Edith
  • Narod, Steven A.
  • Rennert, Gad|||0000-0002-8512-068X
  • Paluch, Shani Shimon
  • Laitman, Yael
  • Friedman, Eitan|||0000-0002-6745-1733
  • Liljegren, Annelie
  • Rantala, Johanna
  • Stenmark-Askmalm, Marie
  • Loman, Niklas
  • Imyanitov, Evgeny N.
  • Hamann, Ute|||0000-0001-6705-7624
  • Spurdle, Amanda B.
  • Healey, Sue
  • Weitzel, Jeffrey N.
  • Herzog, Josef
  • Margileth, David
  • Gorrini, Chiara
  • Esteller, M.|||0000-0003-4490-6093
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Sayols, Sergi|||0000-0002-3877-4170
  • Vidal, Enrique
  • Heyn, Holger|||0000-0002-3276-1889
  • Stoppa-Lyonnet, Dominique
  • Léoné, Melanie
  • Barjhoux, Laure
  • Fassy-Colcombet, Marion
  • De Pauw, Antoine|||0000-0003-3898-073X
  • Lasset, Christine
  • Ferrer, Sandra Fert
  • Castera, Laurent
  • Berthet, Pascaline
  • Cornelis, François
  • Bignon, Yves-Jean
  • Damiola, Francesca
  • Mazoyer, Sylvie
  • Sinilnikova, Olga M.
  • Maxwell, Christopher A.
  • Vijai, Joseph
  • Robson, Mark
  • Kauff, Noah
  • Corines, Marina|||0000-0001-8472-4046
  • Villano, Danylko
  • Cunningham, Julie M.
  • Lee, Adam
  • Lindor, Noralane M.
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Offit, Kenneth
  • Chenevix-Trench, Georgia
  • Couch, Fergus J.
  • Antoniou, Antonis C.
  • Pujana, Miguel Angel|||0000-0003-3222-4044
While interplay between BRCA1 and AURKA-RHAMM-TPX2-TUBG1 regulates mammary epithelial polarization, common genetic variation in HMMR (gene product RHAMM) may be associated with risk of breast cancer in BRCA1 mutation carriers. Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers. Forty-one single nucleotide polymorphisms (SNPs) were genotyped in 15,252 BRCA1 and 8,211 BRCA2 mutation carriers and subsequently analyzed using a retrospective likelihood approach. The association of HMMR rs299290 with breast cancer risk in BRCA1 mutation carriers was confirmed: per-allele hazard ratio (HR) = 1.10, 95% confidence interval (CI) 1.04 - 1.15, p = 1.9 x 10 -4 (false discovery rate (FDR)-adjusted p = 0.043). Variation in CSTF1, located next to AURKA, was also found to be associated with breast cancer risk in BRCA2 mutation carriers: rs2426618 per-allele HR = 1.10, 95% CI 1.03 - 1.16, p = 0.005 (FDR-adjusted p = 0.045). Assessment of pairwise interactions provided suggestions (FDR-adjusted p values.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, Francesca|||0000-0002-2342-7010
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Aguilar, Helena
  • Serra-Musach, Jordi
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Boni, Jacopo|||0000-0003-2626-9393
  • Maicas, Miren|||0000-0003-1404-5552
  • Du, Shisuo
  • Iorio, Francesco|||0000-0001-7063-8913
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Islam, Abul
  • Prado, X.
  • Llorente, Alicia
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Vidal, August|||0000-0001-5727-2099
  • Català, Isabel
  • Soler, Teresa
  • Venturas, G.
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Serra, Helena
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Lozano, José
  • Canals, Francesc|||0000-0002-0650-1135
  • Sieuwerts, Anieta M.
  • De Weerd, Vanja
  • Look, Maxime P.
  • Puertas, Sara
  • García, Nadia
  • Perkins, Archibald S.
  • Bonifaci, Núria|||0000-0002-8193-6825
  • Skowron, Margaretha A.
  • Gómez-Baldó, Laia
  • Hernández, Vanessa
  • Martínez-Aranda, Antonio
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Serrat Farran, Xènia|||0000-0001-7611-5400
  • Cerón, Julián|||0000-0003-4739-2243
  • Brunet, Joan|||0000-0003-1945-3512
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil, Mercedes|||0000-0002-7387-2139
  • Falo, Catalina|||0000-0002-5714-6823
  • Fernández, Adela
  • Morilla, Idoia
  • Pernas, Sonia|||0000-0002-1485-5080
  • Plà, Maria Jesus
  • Andreu, Xavier
  • Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746
  • Ballester, Rosa|||0000-0002-7870-4185
  • Castellà Fernández, Eva
  • Nellist, Mark D.
  • Morales, Saleta
  • Valls, Joan|||0000-0002-4806-7568
  • Velasco Sánchez, Ana
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Figueras, Agnes
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
  • Cordero Casanovas, Alex|||0000-0002-2224-7122
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • Palomero, Luis|||0000-0002-9144-1017
  • Gomez-Caamaño, Antonio|||0000-0002-9773-4590
  • Gajewski, Thomas F.
  • Cohen, Ezra E. W.
  • Jesiotr, Marzena
  • Bodnar, Lubomir
  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Valdés-Mas, Rafael
  • Puente, Xose S.|||0000-0001-9525-1483
  • Viñals, Francesc|||0000-0002-9918-6751
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Graupera, Mariona|||0000-0003-4608-4185
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Garcia-Alonso, Luz|||0000-0002-7863-9619
  • Saez-Rodriguez, J.
  • Esteller, M.|||0000-0003-4490-6093
  • Sierra-Jimenez, Angels|||0000-0003-1023-3492
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Matheu Fernandez, Ander
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Nanjundan, Meera
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Odero, Maria D.|||0000-0002-8858-2054
  • Martens, John W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, Mary Helen
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.